Partnering with Purdue University, Nanotec firm IdentifySensors Biologics unveils what it is calling, “an all-new diagnostic technology platform that detects numerous pathogens, including COVID-19, using electronic nanosensors.” Completing research and testing, the Check4 platform is entering the commercialization stage where engineers are finalizing designs for large-scale, roll-to-roll manufacturing.
Check4 is a pathogen-testing platform that rapidly and accurately detects a wide range of infections, including COVID-19, Influenza, Hepatitis C, Lyme and HIV. The reusable reader sends results to a user’s smartphone. What makes Check4 unique is it use of nanosensors to replace 50-year-old chemical diagnostics. IdentifySensors Biologics CEO, Gregory Hummer, MD believes this approach will “significantly disrupt the $50-billion diagnostics industry, not only for COVID-19, but for a wide range of diseases.”
When it hits the market, Check4 debuts as an over-the-counter, reusable reader that integrates with a user’s smartphone. Single-use test cartridges, sold separately, slide into the reusable reader and send test results from a saliva sample to a phone in minutes. Each test cartridge is set to cost less than $25.
Unlike a chemical PCR test, Check4 requires no amplification, reagents, or lab work and, allegedly, test accuracy often surpasses PCR tests. In the very near future, Purdue University will develop test cartridges for Influenza, Lyme, HIV, and MRSA and the company plans to seek FDA approval this summer.
Curious about nanosensors and their use for fingering heinous, noxious pathogens? Then visit IdentifySensors Biologics.
| email@example.com | 1-516-422-1431 |